Exact Therapeutics A.S. (EXTX)

Overview

EXACT Therapeutics AS is a forward-thinking biopharmaceutical entity at the clinical stage, focusing on the creation of a ground-breaking technology platform known as Acoustic Cluster Therapy (ACT). ACT represents a revolutionary ultrasound-mediated approach aimed at enhancing the efficacy of drug treatments targeted at specific diseases. This technology has the potential to significantly improve the outcomes of various therapeutic agents used in the treatment of a broad spectrum of diseases, including oncology, infectious diseases, and brain-related conditions. Originally established as Phoenix Solutions AS, EXACT Therapeutics AS was incorporated in 2012 and has since been dedicated to advancing its innovative platform from its headquarters in Oslo, Norway. The company has embarked on a Phase I multi-center international clinical trial to evaluate the effectiveness of its ACT platform in treating liver metastases that have originated from colorectal or pancreatic cancer. Furthermore, EXACT Therapeutics AS has formed a strategic collaboration with GE Healthcare aimed at researching the response of immunotherapies in treating solid tumors using the ACT technology.

Products and Services

• Acoustic Cluster Therapy (ACT)

An innovative therapeutic enhancement platform that utilizes ultrasound technology to potentially improve the effectiveness of drugs used in the treatment of various diseases. ACT is particularly being investigated for its application in oncology, infectious diseases, and neurological conditions. By focusing on targeted drug enhancement, ACT seeks to amplify the clinical utility and patient outcomes associated with these therapeutic agents.

• Clinical Trials for Liver Metastases Treatment

EXACT Therapeutics AS is conducting a Phase I multi-center international clinical trial aimed at assessing the efficacy of its ACT platform in patients with liver metastases secondary to colorectal or pancreatic cancer. This trial represents a critical step in validating ACT’s potential in enhancing treatment effectiveness for patients suffering from cancer.

• Collaboration with GE Healthcare

A strategic partnership with GE Healthcare to further research the effectiveness of immunotherapy responses in solid tumors when applied in conjunction with the ACT technology. This collaboration underscores the company's commitment to exploring novel ways to improve therapeutic outcomes for patients battling solid tumors through enhanced drug delivery methods.